The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trials Not Allowed)

Funding Opportunity RFA-CA-19-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. The ETCTN Pharmacokinetic Resource Laboratories will assure the availability of physicians, clinical pharmacologists, nurses and scientists who have the appropriate expertise in pharmacokinetic studies for early drug development and translational research. This FOA solicits U24 cooperative agreement applications from multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding